VRAX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.149

Open

0.147

VWAP

0.14

Vol

3.21M

Mkt Cap

1.11M

Low

0.134

Amount

464.72K

EV/EBITDA(TTM)

--

Total Shares

7.42M

EV

-27.54K

EV/OCF(TTM)

--

P/S(TTM)

231.36

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Show More

Events Timeline

(ET)

2025-12-18

16:20:00

Virax Biolabs Files to Sell 25.875M Ordinary Shares

2025-11-03 (ET)

2025-11-03

08:32:19

Virax finishes enrolling patients for its clinical trial assessing ViraxImmun.

2025-08-26 (ET)

2025-08-26

07:33:03

Virax Biolabs Collaborates with Emory University for ViraxImmune Clinical Trials

2025-07-18 (ET)

2025-07-18

22:22:29

Virax Biolabs receives noncompliance notice from Nasdaq

2025-03-18 (ET)

2025-03-18

07:32:36

Virax Biolabs enrolls first patients in T-cell dysfunction study

2024-12-10 (ET)

2024-12-10

06:31:33

Virax Biolabs enters non-exclusive distribution agreement with Tebubio

2024-10-23 (ET)

2024-10-23

07:34:49

Virax Biolabs announces distribution agreement with Europa Biosite

News

PRnewswire

04-14PRnewswire

Virax Biolabs Advances U.S. Market Strategy with ViraxImmune™

Newsfilter

04-14Newsfilter

Virax Biolabs Advances U.S. Market Strategy with ViraxImmune™

PRnewswire

03-31PRnewswire

Virax Biolabs Achieves ISO Certifications for Quality Management

Newsfilter

03-31Newsfilter

Virax Biolabs Achieves ISO 13485 and ISO 9001 Certifications

PRnewswire

2025-12-04PRnewswire

Virax Biolabs Closes $5 Million Private Placement to Extend Cash Runway

Newsfilter

2025-12-04Newsfilter

Virax Biolabs Secures $5 Million Funding to Extend Cash Runway into 2028

1 Analyst Rating

Wall Street analysts forecast VRAX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.00

Averages

1.00

High

1.00

Current: 0.000

Low

1.00

Averages

1.00

High

1.00

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

$3 -> $1

AI Analysis

2026-01-09

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$3 -> $1

AI Analysis

2026-01-09

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Virax Biolabs to $1 from $3 and keeps a Buy rating on the shares. Virax Biolabs outlined 2026 priorities focused on advancing ViraxImmune for Post-Acute Infection Syndromes, including reporting initial data from two fully enrolled U.K. studies in 2Q26 to support potential MHRA submission, launching a U.S. long COVID study with Emory University, and expanding ImmuneSelect RUO commercialization, the analyst tells investors in a research note. Recent mechanistic data show clear T-cell exhaustion and dysfunction in PAIS patients, consistent with the immune signatures ViraxImmune is designed to detect, with the company's current market value estimated at approximately $26M, the firm says.

Valuation Metrics

The current forward P/E ratio for Virax Biolabs Group Ltd (VRAX.O) is 0.00, compared to its 5-year average forward P/E of -3.17. For a more detailed relative valuation and DCF analysis to assess Virax Biolabs Group Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.17

Current PE

0.00

Overvalued PE

1.94

Undervalued PE

-8.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.45

Current EV/EBITDA

0.29

Overvalued EV/EBITDA

4.21

Undervalued EV/EBITDA

-7.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

49.73

Current PS

281.16

Overvalued PS

167.75

Undervalued PS

-68.28

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

low float,< $10

Intellectia · 1535 candidates

Price: <= $10.00Floating Shares: <= 50,000,000

Ticker

Name

Market Cap$

zSpace, Inc.

3.37M

Cheetah Net Supply Chain Service Inc (Pre-Reincorporation)

5.82M

Propanc Biopharma Inc

1.77M

Functional Brands Inc

1.96M

Dreamland Ltd

4.96M

iSpecimen Inc

4.05M

all penny stocks out there

Intellectia · 1059 candidates

Region: USPrice: $0.00 - $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

iSpecimen Inc

3.23M

Maison Solutions Inc

4.26M

Virax Biolabs Group Ltd

1.10M

Cheetah Net Supply Chain Service Inc (Pre-Reincorporation)

60.78M

VolitionRX Ltd

25.37M

Lixiang Education Holding Co Ltd

3.45M

Intellectia · 2 candidates

Region: USPrice: $0.01 - $0.25Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Virax Biolabs Group Ltd

1000.00K

Nocera Inc

3.02M

top penny stocks under $0.25

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

iSpecimen Inc

3.80M

Wellgistics Health Inc

12.58M

zSpace, Inc.

2.85M

Virax Biolabs Group Ltd

1000.00K

Hyperscale Data Inc

62.91M

CXApp Inc

10.40M

include most volitle

Intellectia · 20 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASEIntraday Amplitude: >= 5

Ticker

Name

Market Cap$

Quince Therapeutics Inc

10.20M

Hyperscale Data Inc

54.64M

Inno Holdings Inc

8.75M

Virax Biolabs Group Ltd

1.11M

Hub Cyber Security Ltd

431.94K

NUBURU Inc

29.16M

What are the top penny stocks under $0.25

Intellectia · 26 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Quince Therapeutics Inc

10.20M

Hyperscale Data Inc

54.64M

Inno Holdings Inc

8.75M

Virax Biolabs Group Ltd

1.11M

Hub Cyber Security Ltd

431.94K

NUBURU Inc

29.16M

penny stocks under $1.00

Intellectia · 330 candidates

Price: $0.00 - $1.00Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Jet.AI Inc

9.67M

zSpace, Inc.

3.46M

Quince Therapeutics Inc

4.87M

Cenntro Inc (The Corporation)

10.22M

Hub Cyber Security Ltd

161.60K

Scworx Corp

1.98M

list of IPO from 2023

Intellectia · 1210 candidates

Region: USFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

623.70K

Erayak Power Solution Group Inc

684.91K

Biodexa Pharmaceuticals PLC

792.57K

Aditxt Inc

829.40K

Brenmiller Energy Ltd

859.02K

Interactive Strength Inc

865.12K

Low float stock screener

Intellectia · 1484 candidates

List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

638.91K

La Rosa Holdings

711.55K

Erayak Power Solution Group Inc

831.04K

NewGenIvf Group Ltd

864.77K

Quhuo Ltd

948.08K

Biodexa Pharmaceuticals PLC

1.01M

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

Whales Holding VRAX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Virax Biolabs Group Ltd (VRAX) stock price today?

The current price of VRAX is 0.1499 USD — it has decreased -1.32

What is Virax Biolabs Group Ltd (VRAX)'s business?

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

What is the price predicton of VRAX Stock?

Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Virax Biolabs Group Ltd (VRAX)'s revenue for the last quarter?

Virax Biolabs Group Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Virax Biolabs Group Ltd (VRAX)'s earnings per share (EPS) for the last quarter?

Virax Biolabs Group Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Virax Biolabs Group Ltd (VRAX). have?

Virax Biolabs Group Ltd (VRAX) has 19 emplpoyees as of April 20 2026.

What is Virax Biolabs Group Ltd (VRAX) market cap?

Today VRAX has the market capitalization of 1.11M USD.